Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
MEI Pharma, Inc.
Nurix Therapeutics, Inc.
Massachusetts General Hospital
Cedars-Sinai Medical Center
Eli Lilly and Company
City of Hope Medical Center
Ascentage Pharma Group Inc.
Hackensack Meridian Health
Newave Pharmaceutical Inc
Schrödinger, Inc.
Mayo Clinic
LTZ Therapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute
AbbVie
AbbVie
Novartis
Acerta Pharma BV
UNC Lineberger Comprehensive Cancer Center
University of California, San Francisco
University of Colorado, Denver
OncoNano Medicine, Inc.
Verismo Therapeutics
British Columbia Cancer Agency
Carna Biosciences, Inc.
Sana Biotechnology
National Cancer Institute (NCI)
City of Hope Medical Center
PeproMene Bio, Inc.
National Cancer Institute (NCI)
University of Arizona
Case Comprehensive Cancer Center
Incyte Corporation
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
Accutar Biotechnology Inc
Sana Biotechnology
Iksuda Therapeutics Ltd.
University of Maryland, Baltimore
Jonsson Comprehensive Cancer Center
Incyte Corporation
Weill Medical College of Cornell University
Stanford University
City of Hope Medical Center
Roswell Park Cancer Institute
PharmaEngine
Adicet Therapeutics
Peking University Cancer Hospital & Institute
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center